Chordate Medical Holding
6.8
SEK
-6.59 %
Less than 1K followers
CMH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-6.59%
+5.92%
-39.01%
-13.79%
-57.11%
-70.34%
-96.7%
-96.18%
-99.6%
Chordate Medical Holding is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulatory and drug-free treatment technique for chronic migraine and chronic rhinitis. The treatment has proven efficacy according to a clinical study and is marketed in selected markets in the EU and the Middle East. The company is headquartered in Kista.
Read moreMarket cap
18.36M SEK
Turnover
36K SEK
Revenue
660K
EBIT %
-4,159.09 %
P/E
-
Dividend yield-%
-
Financial calendar
29.8
2025
Interim report Q2'25
21.11
2025
Interim report Q3'25
All
Press releases
ShowingAll content types
Chordate Medical Holding AB (publ) Interim Report January-March 2025
Communiqué from the Annual General Meeting of Chordate Medical Holding AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools